Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 2,600 shares of Omada Health stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $19.02, for a total transaction of $49,452.00. Following the completion of the sale, the chief financial officer owned 166,659 shares in the company, valued at $3,169,854.18. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Omada Health Price Performance
Shares of OMDA stock opened at $20.89 on Monday. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92. The company’s fifty day simple moving average is $16.51 and its 200-day simple moving average is $14.84. The firm has a market cap of $1.24 billion and a PE ratio of -77.37.
Omada Health (NASDAQ:OMDA – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The business had revenue of $78.05 million during the quarter. On average, equities analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Omada Health
Wall Street Analyst Weigh In
OMDA has been the topic of a number of recent research reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research report on Monday, June 22nd. BMO Capital Markets decreased their price target on Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. JPMorgan Chase & Co. lowered their price target on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Omada Health has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.
Check Out Our Latest Stock Report on Omada Health
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
